A Review on Poly (ADP-ribose) Polymerase (PARP) - An Enzyme that Share the ability to Catalyze the Transfer of ADP-Ribose to Target Proteins

Wajid Ahmad, Rihan Jawed, Irfan Khan, Rizwan Khallel, Danish Hakam
{"title":"A Review on Poly (ADP-ribose) Polymerase (PARP) - An Enzyme that Share the ability to Catalyze the Transfer of ADP-Ribose to Target Proteins","authors":"Wajid Ahmad, Rihan Jawed, Irfan Khan, Rizwan Khallel, Danish Hakam","doi":"10.52711/2231-5713.2023.00040","DOIUrl":null,"url":null,"abstract":"The Poly (ADP-ribose) polymerase (PARP) family has many vital capabilities in cellular processes, together with the law of transcription, apoptosis, and the DNA damage reaction. PARP1 possesses Poly (ADP-ribose) pastime and whilst activated via DNA harm, adds branched PAR chains to facilitate the recruitment of different restore proteins to promote the restore of DNA unmarried-strand breaks. PARP inhibitors (PARP1) had been the first approved cancer drugs that in particular focused the DNA damage response in BRCA1/2 mutated ovarian cancers. Considering the fact that then, there have been sizable advances in our know-how of the mechanisms in the back of sensitization of tumors to PARP inhibitors and enlargement of the use of PARP1 to treat several different most cancers types. right here, we assessment the current advances inside the proposed mechanisms of motion of PARP1, biomarkers of the tumor reaction to PARP1, clinical advances in PARP1 therapy, together with the capacity of mixture treatment plans and mechanisms of tumor resistance.","PeriodicalId":8527,"journal":{"name":"Asian Journal of Pharmacy and Technology","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2023-08-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Asian Journal of Pharmacy and Technology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.52711/2231-5713.2023.00040","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

The Poly (ADP-ribose) polymerase (PARP) family has many vital capabilities in cellular processes, together with the law of transcription, apoptosis, and the DNA damage reaction. PARP1 possesses Poly (ADP-ribose) pastime and whilst activated via DNA harm, adds branched PAR chains to facilitate the recruitment of different restore proteins to promote the restore of DNA unmarried-strand breaks. PARP inhibitors (PARP1) had been the first approved cancer drugs that in particular focused the DNA damage response in BRCA1/2 mutated ovarian cancers. Considering the fact that then, there have been sizable advances in our know-how of the mechanisms in the back of sensitization of tumors to PARP inhibitors and enlargement of the use of PARP1 to treat several different most cancers types. right here, we assessment the current advances inside the proposed mechanisms of motion of PARP1, biomarkers of the tumor reaction to PARP1, clinical advances in PARP1 therapy, together with the capacity of mixture treatment plans and mechanisms of tumor resistance.
聚(adp -核糖)聚合酶(PARP)——一种具有催化adp -核糖向靶蛋白转移能力的酶的研究进展
聚(adp -核糖)聚合酶(PARP)家族在细胞过程中具有许多重要的功能,包括转录、凋亡和DNA损伤反应。PARP1具有Poly (adp -核糖)消遣,当通过DNA损伤激活时,增加支链PAR链以促进不同恢复蛋白的招募,从而促进DNA未结链断裂的恢复。PARP抑制剂(PARP1)是第一个被批准的癌症药物,特别关注BRCA1/2突变卵巢癌的DNA损伤反应。考虑到这一事实,我们对肿瘤对PARP抑制剂致敏的机制的知识已经取得了相当大的进步,并且扩大了PARP1治疗几种不同类型的大多数癌症的使用。在这里,我们评估了PARP1的运动机制,肿瘤对PARP1反应的生物标志物,PARP1治疗的临床进展,以及混合治疗方案和肿瘤耐药机制的能力。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信